Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

Leukemia

Volumn 26, Issue 4, 2012, Pages 830-834

  Kellner, C ^a   Hallack, D ^a   Glorius, P ^a   Staudinger, M ^a   Mohseni Nodehi, S ^a   De Weers, M ^b   Van De Winkel, J G J ^b,c   Parren, P W H I ^b   Stauch, M ^d   Valerius, T ^a   Repp, R ^a   Humpe, A ^a   Gramatzki, M ^a   Peipp, M ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GENMAB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Onkologische Schwerpunktpraxis   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD20 ANTIBODY; CD69 ANTIGEN; DARATUMUMAB; HYBRID PROTEIN; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7D8; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA 7D8; PROTEIN ULBP2 7D8; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; CELL DIVISION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GEL FILTRATION; HUMAN; HUMAN CELL; LETTER; LYMPHOMA CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; UPREGULATION;

EID: 84859644562     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.288     Document Type: Letter

References (11)

1. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495- 502.
2. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 1999; 285: 727-729.
3. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944- 5958.
4. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955- 1962.
5. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940- 3947.
6. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2010; 96: 284- 290.
7. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848.
8. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730- 732.
9. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003; 4: 557- 564.
10. Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A et al. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer 2009; 125: 212- 221.
11. Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 2010; 70: 10121-10130.